Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Frequency Therapeutics, Inc. Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results August 10, 2023 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results May 12, 2023 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results March 10, 2023 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Participate at Upcoming March Investor Conferences February 27, 2023 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss February 13, 2023 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss December 15, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results November 17, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results November 08, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss October 12, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Participate in September Investor and Medical Conferences August 30, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results August 09, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference May 18, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results May 04, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference April 22, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results March 15, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences February 28, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference January 04, 2022 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise December 09, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results November 15, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis November 09, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program October 27, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint October 21, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points September 22, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Present at Upcoming Investor Conferences September 08, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results August 12, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences May 25, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss May 20, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results May 13, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science April 13, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference April 09, 2021 From Frequency Therapeutics, Inc. Via Business Wire Tickers FREQ Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.